Common-Size Income Statement
Paying user area
Try for free
AbbVie Inc. pages available for free this week:
- Statement of Comprehensive Income
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to FCFF (EV/FCFF)
- Dividend Discount Model (DDM)
- Return on Equity (ROE) since 2012
- Return on Assets (ROA) since 2012
- Total Asset Turnover since 2012
- Price to Book Value (P/BV) since 2012
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AbbVie Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
AbbVie Inc., common-size consolidated income statement
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
| Income statement item | Description | The company |
|---|---|---|
| Operating earnings | The net result for the period of deducting operating expenses from operating revenues. | AbbVie Inc. operating earnings as a percentage of net revenues decreased from 2021 to 2022 and from 2022 to 2023. |
| Earnings before income tax expense | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. | AbbVie Inc. earnings before income tax expense as a percentage of net revenues increased from 2021 to 2022 but then decreased significantly from 2022 to 2023. |
| Net earnings attributable to AbbVie Inc. | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | AbbVie Inc. net earnings attributable to AbbVie Inc. as a percentage of net revenues decreased from 2021 to 2022 and from 2022 to 2023. |